Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDWART and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
NCT02545010Phase 1Unknown
- Sponsor
- National University Hospital
- Start
- Sep 2015
- Primary completion
- Aug 2017
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Paclitaxel Micelles for Injection in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma (PFTC), sponsored by National University Hospital. Primary endpoint: Maximal Tolerated Dose at 6 weeks. Status: unknown.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT02545010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545010.